ERBB2 and breast carcinoma: Furthermore, high intra-tumoral levels of immune-related genes, including those associated with type I interferon responses, and the presence of CD8+ cytotoxic T lymphocytes, correlate with improved disease outcome in patients with ERBB2+ breast cancer and TNBC (6, 7).